Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies

OVG's Andrew Pollard joins the Fellowship of the Academy of Medical Sciences

47 world leading UK researchers, including the Department of Paediatrics' Georg Hollander and Andrew Pollard have been elected to the prestigious Fellowship of the Academy of Medical Sciences.

The Fellows have been elected for their contribution to medical research and healthcare, the generation of new knowledge in medical sciences and its translation into benefits to society.

Read more here

Similar stories

First volunteer vaccinated in the world's first Bundibugyo ebolavirus vaccine trial

Friday 24th July, Oxford - The University of Oxford’s Oxford Vaccine Group has successfully vaccinated the first volunteer in the world’s first clinical trial of a vaccine designed to protect against Bundibugyo ebolavirus (BDBV).

BD-Ebov trial advances following completion of sentinel vaccinations

The Oxford Vaccine Group has reached an important milestone in the BD-Ebov clinical trial, with the first five participants now vaccinated as part of the study's sentinel group.

World’s first Phase I Bundibugyo ebolavirus vaccine trial launched by Oxford Vaccine Group

Monday 13 July, Oxford: The University of Oxford’s Oxford Vaccine Group has launched the world’s first Phase I clinical trial, BD-Ebov, of a vaccine against Bundibugyo ebolavirus (BDBV), in response to the ongoing outbreak in the Democratic Republic of the Congo and neighbouring Uganda.

Statement on vaccine efforts relating to the Bundibugyo Ebolavirus outbreak in the DRC

In response to the current Bundibugyo Ebolavirus outbreak in the Democratic Republic of the Congo, the Oxford Vaccine Group (OVG) is working urgently with Oxford’s own Clinical BioManufacturing Facility and the Serum Institute of India Pvt. Ltd. (SIIPL), to rapidly produce and scale doses of our ChAdOx-based monovalent Bundibugyo Ebolavirus candidate vaccine, ChAdOx1 BDBV.

Dr Young Chan Kim receives international vaccine research award

Dr Young Chan Kim has been awarded the 2026 Early Career Researcher Award at the 20th Vaccine Congress, one of the leading international conferences in vaccinology organised by Vaccine, Elsevier’s premier journal in the field.

Dr Young Chan Kim appointed Director of Graduate Studies

Dr Young Chan Kim has been appointed Director of Graduate Studies (DGS) in the Department of Paediatrics.

Similar stories

First volunteer vaccinated in the world's first Bundibugyo ebolavirus vaccine trial

Friday 24th July, Oxford - The University of Oxford’s Oxford Vaccine Group has successfully vaccinated the first volunteer in the world’s first clinical trial of a vaccine designed to protect against Bundibugyo ebolavirus (BDBV).

BD-Ebov trial advances following completion of sentinel vaccinations

The Oxford Vaccine Group has reached an important milestone in the BD-Ebov clinical trial, with the first five participants now vaccinated as part of the study's sentinel group.

World’s first Phase I Bundibugyo ebolavirus vaccine trial launched by Oxford Vaccine Group

Monday 13 July, Oxford: The University of Oxford’s Oxford Vaccine Group has launched the world’s first Phase I clinical trial, BD-Ebov, of a vaccine against Bundibugyo ebolavirus (BDBV), in response to the ongoing outbreak in the Democratic Republic of the Congo and neighbouring Uganda.

Statement on vaccine efforts relating to the Bundibugyo Ebolavirus outbreak in the DRC

In response to the current Bundibugyo Ebolavirus outbreak in the Democratic Republic of the Congo, the Oxford Vaccine Group (OVG) is working urgently with Oxford’s own Clinical BioManufacturing Facility and the Serum Institute of India Pvt. Ltd. (SIIPL), to rapidly produce and scale doses of our ChAdOx-based monovalent Bundibugyo Ebolavirus candidate vaccine, ChAdOx1 BDBV.

Dr Young Chan Kim receives international vaccine research award

Dr Young Chan Kim has been awarded the 2026 Early Career Researcher Award at the 20th Vaccine Congress, one of the leading international conferences in vaccinology organised by Vaccine, Elsevier’s premier journal in the field.

Dr Young Chan Kim appointed Director of Graduate Studies

Dr Young Chan Kim has been appointed Director of Graduate Studies (DGS) in the Department of Paediatrics.